The antibiotic he didn’t need will be paid for by someone else.

He had a cold, insisted, and left the consultation with a prescription for antibiotics he did not need. Nothing happened to him. That is the hardest part to explain: in economics, an externality is a cost paid by someone other than the person who generates it, and few things in health illustrate it better. The prescriber does not pay for the resistance they helped create, and neither does he. It will be paid for by tomorrow’s hospital and by a person somewhere else. This week, WHO and its partners devote their annual campaign to antimicrobial resistance under the slogan of one health and one action, and in May the World Health Assembly adopted the global action plan for 2026–2036.
The scale of the problem was estimated by the GRAM project, published in The Lancet in September 2024. Since 1990, bacterial resistance has caused more than a million attributable deaths every year: 1.14 million in 2021, with 4.71 million associated deaths in the same year. These are two different measures that must not be mixed up: attributable is the death that would not have occurred without resistance; associated is the death of someone with a resistant infection. Under the reference scenario, which assumes that trends do not change, the projection to 2050 is 1.91 million attributable deaths a year and 8.22 million associated, and, cumulatively between 2025 and 2050, 39.1 million attributable and 169 million associated. These are projections with wide intervals, that is, orders of magnitude conditional on their assumptions, and that is how they should be read. For this part of the world, the study projects Latin America and the Caribbean among the super-regions with the highest rates in 2050; it is not an estimate for Chile.
The same study modelled alternative scenarios, and here it is worth reading carefully what each one measures. With better care for serious infections and better access to the right antibiotics, the model averts 92 million deaths from infections, resistant and susceptible, over the period. With new drugs against Gram-negative bacteria, it averts 11 million deaths attributable to resistance. These are two different variables on two different populations, and they do not entitle anyone to say that one lever is bigger than the other. What they do say is that everyday clinical management, preventing infections, diagnosing on time, making good use of what exists, has an enormous modelled effect by itself, without waiting for the pharmacy of the future.
What does a board have to do with his prescription? Everything, if the hospital it runs has an antimicrobial stewardship programme and measures it, and nothing, if it regards it as a matter for infectious disease specialists. There are indicators to start with, and they are working proposals, not universal standards: antimicrobial consumption per thousand bed-days, with a defined denominator and case mix; the proportion of prescriptions reviewed at 48 or 72 hours; and the rate of infections by monitored resistant organisms. A board that asks for none of them does not know what debt it is taking on.
His antibiotic will be billed later. The only open question is to whom.
Sources: GBD 2021 Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. Lancet 2024;404(10459):1199-226. https://doi.org/10.1016/S0140-6736(24)01867-1 · Free full text · WHO. World AMR Awareness Week 2026. · WHO. World Health Assembly adopts the updated Global Action Plan on AMR (2026–2036), 25-05-2026. · MINSAL / ISP. National HAI programme and resistance surveillance.